An approach for new anticancer drugs:Oncogene-targeted antisense DNA

The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides

“…Unlike the cationic polystyrene described above, the charges on the surface of PCAs are not part of the chemical structure of the polymer, as they are introduced in the system at the time of complexation with ODNs. These investigations were commenced by a group at the Centre National de la Recherche Scientifique in Paris, which provided most of the results currently available [151][152][153][154][155][156]. As mediators for ion-pair formation, hydrophobic cations such as quaternary ammonium salts or tetraphenylphosphomium chloride were proposed; in the majority of experiments, cetyltrimethylammonium bromide was added to ODN prior to complexation to the polymer nanoparticles.…”

A journey through the emergence of nanomedicines with poly(alkylcyanoacrylate) based nanoparticles

“…and to the delivery of anticancer drugs in resistant cells (see section 4.2.2.3.). The strength of a large body of works done with PACA nanoparticles strands on studies based on clearly identified clinical perspectives having included in vivo evaluations on animal models of the corresponding diseases (see for instance Damgé et al, 1988, Fattal et al, 1989, Chiannikulchai et al, 1989, Chavany et al, 1992, Schwab et al, 1994, Brigger et al, 2004, Calvo et al, 2001a, Juenet et al, 2017, Fusser et al, 2019. Following such an approach has been reminded as an urgent necessity to make progress in clinical translation of nanomedicines in recent articles analysing the clinical output of the considerable amount of works done on nanomedicines , Venditto and Szoka, 2013, Dai et al, 2018.…”

“…PACA nanoparticles were among the first drug carriers tested to explore proofs of concept of cancer treatments using these very new APIs. They were first explored in the case of the delivery of AsODN [Chavany et al, 1992, Schwab et al, 1994 and then considered as delivery system to administer siRNA demonstrating the feasibility of intravenous treatments [Toub et al, 2005, De Martimprey et al, 2009. Beside exploring treatments based on the delivery of nucleic acids, the potential of PACA nanoparticles has been investigated for treatment based on oral administration of peptides to treat metabolic diseases with diabetes at the forefront (see section 4.2.2.1.)…”

Influence of nanoparticles on morphological differentiation of mouse embryonic stem cells

“…It was surmised that cytoskeletal reorganization might be involved as evident from the smaller cell surface area of ES cells after nanoparticle exposure. Furthermore, nanoparticles have been shown to stabilize messenger RNA and to stimulate protein release; these 2 events have a direct effect on differentiation (48).…”